Over the past 10 years, the available evidence on the treatment of malaria during pregnancy has increased substantially. Owing to their relative ease of use, good sensitivity and specificity, histidine rich protein 2 based rapid diagnostic tests are appropriate for symptomatic pregnant women; however, such tests are less appropriate for systematic screening because they will not detect an important proportion of infections among asymptomatic women. The effect of pregnancy on the pharmacokinetics of antimalarial drugs varies greatly between studies and class of antimalarial drugs, emphasising the need for prospective studies in pregnant and non-pregnant women. For the treatment of malaria during the first trimester, international guidelines are being reviewed by WHO. For the second and third trimester of pregnancy, results from several trials have confirmed that artemisinin-based combination treatments are safe and efficacious, although tolerability and efficacy might vary by treatment. It is now essential to translate such evidence into policies and clinical practice that benefit pregnant women in countries where malaria is endemic. Access to parasitological diagnosis or appropriate antimalarial treatment remains low in many countries and regions. Therefore, there is a pressing need for research to identify quality improvement interventions targeting pregnant women and health providers. In addition, efficient and practical systems for pharmacovigilance are needed to further expand knowledge on the safety of antimalarial drugs, particularly in the first trimester of pregnancy. Lancet Infect Dis 2018; 18: e133-46
Introduction
All malaria infections in pregnancy should be treated promptly with safe and efficacious antimalarial drugs to prevent harmful effects on the mother and fetus. 1, 2 Concerns about the potential for harm of new antimalarial treatments on pregnant women or their unborn baby have led to their systematic exclusion from clinical trials, resulting in scarcity of data for their pharmacokinetics, safety, and efficacy during pregnancy, 3-5 particularly for the first trimester. 6,7 However, over the past 10 years, 8 there has been substantial research on malaria in pregnancy by the Malaria in Pregnancy Consortium and others to address gaps in knowledge. Herein, we summarise the results.
Diagnosis
Case management of malaria involves identification of a suspect case, based on the presence of signs or symptoms, diagnostic testing, and treatment, if needed. The accuracy of diagnostic tests depends on parasite density. Microscopy by an experienced and well equipped technician has a detection threshold of 15 parasites per μL of blood, 1 while for rapid diagnostic tests (RDTs), which detect circulating parasite antigens, this threshold can be as low as 200 parasites per μL. 9 Such diagnostic tests might be adequate for pregnant women with malaria symptoms because these individuals usually have parasite densities above the thresholds for detection. 10 However, most infections during pregnancy are asymptomatic, with low parasite densities that are often not detected by microscopy. The public health importance of such infections is controversial because they have been associated with anaemia, reduced mean haemoglobin, low birthweight, and premature births in some studies, 11 but not in others. 12 Intermittent screening and treatment is a potential alternative to intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine in areas with high resistance to sulfadoxine-pyrimethamine or low malaria transmission. The effectiveness of such screening and treatment is based on the assumption that currently available tests-specifically RDTs-should be able to identify most infections, but this is probably not true; because of their ability to detect circulating parasite antigens, RDTs might be useful in diagnosing placental malaria, particularly for Plasmodium falciparum. 13 In a systematic review of 49 studies, with microscopy of placental blood as the gold standard, RDTs sensitivity was 81% (95% CI and specificity was 94% (76-99), whereas PCR had increased sensitivity (94%, [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] but decreased specificity (77%, [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] . 14 However, in Papua New Guinea, more than half of active placenta infections were not diagnosed by RDT, microscopy, or PCR in peripheral blood. 15 Similar results were reported from Mozambique, 16 possibly because of occult placental sequestration. 15 Nevertheless, in Malawi, latent class analysis (which does not assume a gold standard) showed that RDT sensitivity on peripheral blood for diagnosing placental malaria was 92·7%, and specificity was 91·8%. 17 As for peripheral infections, RDTs had similar 18, 19 or lower 10 sensitivity than did microscopy, with histidine rich protein 2 (HRP2)-based RDT performing better than plasmodium lactate dehydrogenase-based RDTs. 10, 20 Because of their relative ease of use and good sensitivity and specificity, HRP2-based RDTs are appropriate for symptomatic pregnant women; however, they are less e134 www.thelancet.com/infection Vol 18 April 2018 Series useful for systematic screening since these tests are unable to diagnose an important proportion of infections among asymptomatic pregnant women. Ultra-sensitive RDT (such as Malaria Ag P.f; Alere, Waltham, MA, USA) should be evaluated for the detection of low-density infections in pregnant women.
Treatment of uncomplicated malaria First trimester
For P falciparum malaria infections during the first trimester, WHO recommends quinine with clindamycin for 7 days (or quinine alone if clindamycin is not available) and, in situations of failure or unavailability, an artemisininbased combination therapy (ACT) or oral artesunate with clindamycin for 7 days. 2 This recommendation is based on data from 700 pregnant women exposed to artemisinin derivatives during the first trimester, and excludes at least a 4·2-fold increase in risk of major congenital defects. 2 However, the Malaria Policy Advisory Committee has recommended that these guidelines should be revised on the basis of meta-analysis findings. 21, 22 Malaria caused by Plasmodium species other than P falciparum (non-falciparum malaria) should be treated with chloroquine; quinine is recommended for chloroquine-resistant infections. 2
Second and third trimester
Guidelines for the treatment of P falciparum malaria in the second and third trimester are the same as for non-pregnant adults; this means any ACTs that are recommended as first-line treatment-namely, artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, dihydroarte misinin-piperaquine, or artesunate plus sulfadoxinepyrimethamine-can be used in pregnancy. 2 A systematic review 23 of 16 randomised controlled trials done between 1998 and 2009 presented ten trials testing ACTs (three trials of artesunate plus sulfadoxine-pyrimethamine, two of artemether-lumefantrine, three of artesunate-mefloquine, one of dihydroartemisinin-piperaquine, and one of artesunate with atovaquone-proguanil) versus either combinations without artemisinins or monotherapies. In most trials, ACTs had a PCR-adjusted efficacy of more than 90%, with the exception of artemether-lumefantrine at the Thai-Myanmar border, 23 which had an efficacy of 87% at day 42 that was attributed to low drug concentrations and low antimalarial immunity. 24 A systematic review and metaanalysis comparing the efficacy, safety, and tolerance of ACTs with that of quinine and other non-ACT antimalarial drugs (azithromycin plus sulfadoxine-pyrimethamine or amodiaquine plus sulfadoxine-pyrimethamine) included six trials done between 1995 and 2009; three studies were from sub-Saharan Africa (Malawi, Tanzania, and Uganda) and three were from Asia (Thailand), and all of them were included in the previous review, 23 except the study in Uganda. 25 ACTs were significantly more efficacious than was oral quinine in Thailand and had similar efficacy to non-ACTs in Africa. Birth outcomes were similar between treatment arms, with the exception of mean birthweight, which was significantly higher in ACT recipients than in non-ACT recipients, indicating ACTs might clear parasites (including those in the placenta) more efficiently than do other treatments. 26 Furthermore, artemether-lumefantrine was associated with decreased rates of moderate to highgrade haemozoin deposition in the placenta compared with oral quinine in Uganda (13·3% vs 25·8%), indicating a protective effect against placental malaria. 27 A large multicentre randomised open-label trial testing four ACTs (artemether-lumefantrine, artesunateamodiaquine, artesunate-mefloquine, and dihydro -artemisinin-piperaquine) in pregnant women with P falciparum malaria was done between 2010 and 2013 in four sub-Saharan African countries (Burkina Faso, Ghana, Malawi, and Zambia). In total, 3428 pregnant women were recruited and followed up until day 63 after treatment and again at delivery. PCR-adjusted cure rates for all ACTs ranged from 94·8% to 99·2%, within the prespecified equivalence margin. Nevertheless, the cure rates in the artemether-lumefantrine group were significantly lower than for the other treatments, which had similar high efficacy. 28 The significantly lower unadjusted cure rates in the artemether-lumefantrine group (52·5%) than in the other treatment groups (artesunate-amodiaquine 82·3%; artesunate-mefloquine 73·8%; dihydroartemisinin-piperaquine 86·9%) show that, in areas of intense transmission, dihydroartemisininpiperaquine might be preferable to artemetherlumefantrine because of its longer post-treatment prophylactic period.
A few smaller trials done in sub-Saharan Africa (Nigeria in 2015 29 and Uganda in 2016 30 ) have also shown the high efficacy of ACTs.
In southern Papua, Indonesia, in 2006, dihydroartemisinin-piperaquine became the first-line treatment for malaria in pregnant women in their second and third trimester; as a result, the number of congenital malaria cases decreased from 3·2% to 0·2%, and there have been no cases since 2008. 31 The implementation of dihydroartemisinin-piperaquine also resulted in a decreased risk of malaria at delivery, early neonatal deaths, 32 severe maternal anaemia, and low birthweight. 33 Although chloroquine can be used to treat non-falciparum malaria, 1 Plasmodium vivax resistance emerged in the 1980s in New Guinea and has spread to the Indonesian archipelago and Mekong region. 34 Most antimalarial drugs with activity against P falciparum have intrinsic activity against the asexual stages of P vivax, except antifolate drugs. 34 Therefore, P vivax malaria can be treated with any ACT that is effective against P falciparum, with the exception of artesunate plus sulfadoxine-pyrimethamine. 2 Although ACTs rapidly clear the asexual stages of P vivax, there is high variability in the occurrence of recurrent infection between 28 days and 63 days post-treatment. 34 Primaquine-which is the only available drug effective against the liver stages of the parasite's life cycle-is 55, 56 No difference in exposure to amodiaquine and desethylamodiaquine in pregnant women compared with in post-partum women Summary ·· No difference in exposure reported in pregnant women compared with in non-pregnant women
Piperaquine
Papua New Guinea 32 pregnant women and 33 non-pregnant women 48 Exposure to piperaquine decreased by 42% in pregnant women compared with in non-pregnant women Thailand 24 pregnant women and 24 non-pregnant women 49, 50 No difference in exposure to piperaquine in pregnant women compared with in non-pregnant women Sudan 12 pregnant women and 12 non-pregnant women 57, 58 No difference in exposure to piperaquine in pregnant women compared with in non-pregnant women 
Treatment of complicated malaria
Pregnant women have a higher risk of developing severe malaria. This is particularly true in areas with low transmission of malaria, where severe malaria is often complicated by pulmonary oedema and hypoglycaemia. 2 Intensive care and prompt parenteral antimalarial treatment are crucial to the mother's survival. 1 A review on the treatment of severe malaria in all trimesters of pregnancy identified ten studies that reported clinical outcomes. 35 
Pharmacokinetics
Pregnancy is associated with various physiological changes that can alter the absorption, disposition, metabolism, and excretion of drugs. 36 These pregnancyrelated changes in pharmacokinetic properties could result in overexposure or underexposure to antimalarial drugs. Overexposure might lead to maternal and fetal toxicity and underexposure could cause therapeutic failures, resulting in poor pregnancy outcomes, maternal death, and increased risk of drug resistance. 36, 37 Reports of the pharmacokinetics of antimalarial drugs in pregnancy are often contradictory and based on small studies without non-pregnant control patients (table 1) . Controlled prospective pharmacokinetic studies are needed to evaluate the effect of pregnancy. Ideally, non-pregnant controls should be matched by sex, malaria infection status, and age to control for confounding covariates, and evaluated via pharmacokinetic modelling to quantify potential pregnancy-specific effects.
Artemisinins
Systemic exposure to artesunate and its active metabolite, dihydroartemisinin, after oral administration of artesunate, was substantially lower in pregnant women with P falciparum malaria on the Thai-Myanmar border than in historical 38 and post-partum controls. 39, 40 In one of these studies, malaria and pregnancy had opposite effects on the absorption of orally administered artesunate; malaria increased the oral bioavailability of artesunate by 87%, whereas pregnancy decreased the oral bioavailability by 23%. 39 However, there was no evidence of pregnancy-related alterations of the pharmacokinetic properties of artesunate or dihydroartemisinin after intravenous administration, suggesting that standard treatment recommendations for severe malaria apply to pregnant women. A study carried out in Kinshasa, Democratic Republic of the Congo, which compared women during pregnancy and postpartum with non-pregnant controls, showed that drug exposure changed in pregnant women (42% decrease in exposure to dihydroartemisinin) after oral administration of artesunate. 41, 42 However, no difference in exposure to dihydroartemisinin was seen in pregnant and non-pregnant women in Burkina Faso after oral artesunate treatment. 43 Two clinical studies in pregnant women and matched non-pregnant controls in Uganda 30 and Tanzania 44 reported that the pharmacokinetic properties of artemether and its active metabolite, dihydroartemisinin, were unaltered after oral administration of artemether. However, studies that recruited only pregnant women showed lower drug exposures in pregnant women than did studies of historical controls. [45] [46] [47] 61 Contradictory results have also been presented regarding systemic drug exposure to dihydroartemisinin after oral administration in pregnant women and matched non-pregnant controls. [48] [49] [50] [51] In Thailand and Uganda, drug exposure was substantially lower (Thailand 38% lower, Uganda 47% lower) in pregnant women than in non-pregnant women, 49 whereas in Papua New Guinea pharmacokinetic properties in pregnant women were unaltered. 48 Therefore, it might be necessary to increase doses of ACTs for pregnant women, but more data are needed. A systematic review reached similar conclusions. 70
4-amino-quinolines
Drug exposure to chloroquine and its main metabolite, desethylchloroquine, was significantly reduced (chloroquine 25% reduced, desethylchloroquine 45% reduced) in pregnant women, compared with in age-matched non-pregnant women, in Papua New Guinea when receiving three daily doses (450 mg/day) of chloroquine as IPTp. 52 This difference was due to increased elimination of both chloroquine and desethylchloroquine during pregnancy. However, in another study, pharmacokinetic parameters of chloroquine or desethylchloroquine were not different between pregnant and non-pregnant Karen women with P vivax malaria. 53 There were no differences in the pharmacokinetic properties of amodiaquine or desethylamodiaquine, its main metabolite, between pregnant women in the second and third trimesters with P vivax malaria and the same women at 3 months postpartum. 55 Population pharmacokinetic modelling showed that pregnancy did Series not have a clinically significant effect on the pharmacokinetics of amodiaquine or desethylamodiaquine, with no need for dose adjustment. 56 There have been contradictory results regarding the pharmacokinetic properties of piperaquine in pregnancy. There was no significant difference in total drug exposure to piperaquine between pregnant and nonpregnant women with P falciparum malaria in Thailand. 50 Population pharmacokinetic modelling at the populationlevel showed similar effects of piperaquine on the relative bioavailability and elimination, resulting in a net effect of unaltered drug exposure, but a shorter elimination half-life in pregnant women. 49 Similar results were obtained in pregnant and age-matched and weight-matched nonpregnant Sudanese women with P falciparum malaria. 57, 58 However, exposure to piperaquine was about 40% lower in pregnant women than it was in non-pregnant women in Papua New Guinea 48 and Uganda. 51
Quinoline methanols and related drugs
There were no relevant differences in exposure to mefloquine between pregnant women in their second and third trimester and matched non-pregnant women with P falciparum malaria in Burkina Faso when these women were treated with artesunate-mefloquine. 43 However, peak concentrations of mefloquine were significantly lower in pregnant women than in non-pregnant women with P falciparum malaria treated with a single oral dose of mefloquine. 59 Similarly, a dose-finding study on the Thai-Myanmar border suggests that drug exposure to mefloquine might be decreased in late pregnancy. 60 Mean pharmacokinetic parameters of quinine and its metabolites were not significantly different between Sudanese pregnant and non-pregnant women with P falciparum malaria who received a single dose of quinine hydrochloride (as intravenous infusion over 2 h), suggesting that no dose adjustment is required in pregnancy. 62 However, in these women, exposure to quinine during clinical malaria was higher than it was during the convalescence phase. 63 Similarly, in Uganda, increased exposure to quinine during clinical malaria, compared with the convalescence phase, was reported in pregnant women with P falciparum malaria who were treated with oral quinine. Nevertheless, drug exposure in pregnant women was only about half of that in non-pregnant patients. 61 Systemic drug exposure to lumefantrine is generally lower in pregnant women than in non-pregnant women treated with artemether-lumefantrine for P falciparum malaria. 44, 64, 65 These studies showed a decrease of about 30% in concentrations of lumefantrine on day 7 in pregnant versus non-pregnant patients. However, one study in rural Uganda showed no differences in exposure to lumefantrine between pregnant women and non-pregnant women with P falciparum malaria. 30 
Antifolates
In Papua New Guinea, exposures to sulfadoxine and pyrimethamine were significantly lower in pregnant women than in non-pregnant women. 66 A study in Kenya evaluated the pharmacokinetic properties of sulfadoxine and pyrimethamine in 33 pregnant women and 11 women post partum and had similar results for sulfadoxine, while pyrimethamine was unaffected by pregnancy. 67 A multicentre study (Mali, Mozambique, Sudan, and Zambia) also showed that exposure to sulfadoxine was lower during pregnancy than it was during post partum while reporting higher pyrimethamine exposure during pregnancy. 68 Pharmacokinetic data for both drugs were highly variable among the study sites and did not suggest that dose adjustment was necessary in pregnancy. 68
Drug safety
To date, issues with the methodology of studies have prevented firm conclusions on the safety of antimalarial drugs in pregnancy (table 2) . Studies are often underpowered to detect rare safety outcomes and small differences. The trial design often covers a short or sporadic follow-up period 91 and there is not enough statistical power to adjust for uncontrolled confounders, such as severity of disease or presence of sexually transmitted infections, or both, emphasising the need for continuous safety monitoring.
Artemisinin derivatives and partner drugs
In pregnant rats on gestational day 10, artemisinin derivatives have embryotoxic effects (death, cardiac malformations, and long bone malformations) due to the death of circulating embryonic erythroblasts. 92 In human beings, dihydroartemisinin is responsible for erythrotoxicity. 93, 94 In rats, embryos were most sensitive to the lethal effects of artesunate at gestational days 10-14; the corresponding gestational age in human beings is about 3-9 weeks after conception. 95 Artemisinins concentrate in infected red blood cells while malaria causes hypoferraemia. 96 Therefore, malaria might protect against artemisinin-induced decreases in the number of reticulocytes by reducing the concentrations of active drug or ferrous iron (which activates the drug to toxic free radicals), or both, in target tissues; such protection by malaria against artesunate-induced toxicity has been seen in rats. This finding could also be true for embryotoxicity, which would mean that pregnant women without malaria would be at greater risk of artemisinininduced embryotoxicity. 95 A meta-analysis on 1664 pregnancies that were followed up after treatment with either artemisinin or quinine during the first trimester had no differences in the risk of miscarriage, stillbirth, or major congenital malformations. 22 Risk of miscarriage was similar between women treated with artemisinins during the first trimester and those not treated with an antimalarial; the www.thelancet.com/infection Vol 18 April 2018 e139 Series risk was significantly higher for women treated with quinine than for those not treated with an antimalarial drug. 22, 97 In Thailand, the risk of miscarriage among women attending antenatal clinics between 1986 and 2010 was not significantly different to the risk in those treated between 6 weeks and 12 weeks of gestation with artesunate (31%), quinine (27%), or chloroquine (26%; p=0·71). 90 The risk of miscarriage associated with malaria outweighed any adverse effects from treatment with antimalarial drugs, including artemisinins. 90 In Thailand, 71 pregnant women in their first trimester who were exposed to either artemisinins or quinine had a similar risk of miscarriage. Consideration of only exposure during the embryo-sensitive window (6-13 weeks gestation) showed that the occurrence of congenital malformations for artemisinins or quinine was similar, although the sample size was small (109 pregnancies for artemisinins, 641 pregnancies for quinine). In Kenya, 98 first trimester exposure to artemisinins was reported in 299 (26%) of 1134 pregnant women, in 178 (8%) of 2167 women in Tanzania, 99 in 156 (16%) of 1001 women in Zambia, 100 and in 96 (9%) of 1072 women in Rwanda. 101 In Kenya, 98 the risk of miscarriage was higher among women treated with artemisinins than in women with no exposure to antimalarial drugs; however, this increase was not seen when analysis was restricted to exposure during the embryo-sensitive period, or when women treated with quinine were compared. In Tanzania, 99 adverse pregnancy outcomes (miscarriage, stillbirth, or prematurity) were more common in women treated with quinine than in women treated with any other antimalarial drug, including artemether-lumefantrine. In Zambia, 100 first trimester exposure to antimalarial drugs was not associated with adverse pregnancy outcomes.
A review of artemether-lumefantrine use in sub-Saharan Africa 72 showed that receipt of this treatment in the first trimester of pregnancy did not increase the risk of perinatal or neonatal death or stillbirth. Infant neurodevelopment, birthweight, and overall incidence of birth defects were also similar, irrespective of treatment with artemether-lumefantrine or other antimalarial drugs during the first trimester. All cases of miscarriage in the artemether-lumefantrine exposure group were in patients who had received treatment during the first trimester, although in most cases there were confounding factors. 72 Preclinical data on lumefantrine alone did not show any embryotoxicity. 36 Nevertheless, artemetherlumefantrine is still not recommended for the treatment of malaria during the first trimester of pregnancy unless quinine, with or without clindamycin, has failed or is unavailable.
A systematic review and meta-analysis 102 of second and third trimester exposure to ACTs in studies in Africa and Asia showed that the risk of miscarriage and congenital anomalies is similar among women in the second or third trimester of pregnancy who were treated with artemisinins and women treated with quinine or other
Safety profile
Artemisinin derivatives and partner drugs
Artemisinin derivatives
Artemisinin derivatives in general are well tolerated; concerns regarding safety on pregnancy have limited its use in first trimester; recent studies reported no differences in the risk of miscarriage, stillbirth, or major congenital malformations between artemisinins and quinine used during first trimester 22, 71 Artemether-lumefantrine Artemether-lumefantrine is well tolerated; 28 first trimester of pregnancy: no increase in risk of perinatal death, neonatal death, or stillbirth; 72 second and third trimester: no increase in adverse pregnancy outcomes 73 Amodiaquine-artesunate Amodiaquine-artesunate has been associated with general weakness, vomiting, dizziness, and nausea but without increased risk of miscarriage, stillbirth, or major congenital malformations 28, 74, 75 Dihydroartemisinin-piperaquine Dihydroartemisinin-piperaquine is well tolerated; 28, 50, 57, 58, [76] [77] [78] concerns regarding prolongation of the QT interval were raised; more studies are needed to understand the clinical significance of this event in pregnant women [77] [78] [79] Mefloquine-artesunate Mefloquine-artesunate was less well tolerated when compared with other combinations (artemether-lumefantrine or dihydroartemisinin-piperaquine) ; 28 pregnancy outcomes similar to those of other antimalarial treatments 28 Sulfadoxine-pyrimethamine-artesunate Sulfadoxine-pyrimethamine-artesunate seemed safe and well tolerated [80] [81] [82] Mefloquine Prevalence of birth defects and fetal loss are simlar to background rates in pregnant women exposed to mefloquine; 83 mefloquine is reported to be less well tolerated (increased risk of dizziness and vomiting) than sulfadoxine-pyrimethamine when used for prevention of malaria; when mefloquine alone was used as intermittent preventive treatment, incidence of spontaneous abortions, stillbirths, and congenital anomalies did not differ significantly compared to sulfadoxine-pyrimethamine 84 Sulfadoxine-pyrimethamine When given as an intermittent preventive treatment in pregnancy, sulfadoxine-pyrimethamine does not increase risk of teratogenesis; 85 sulfadoxine-pyrimethamine should not be administered concurrently with co-trimoxazole given their redundant mechanisms of action and synergistic worsening of adverse drug reactions; 86 
no clinical association between sulfadoxine-pyrimethamine and kernicterus has been reported 85
Quinine Quinine is less well tolerated when comparing with other antimalarials and can cause hypoglycaemia and tinnitus, particularly in the second and third trimester; 5,87 prolongation of the QT interval with no significant cardiotoxicity has been reported 88 Chloroquine Chloroquine has been described as safe throughout pregnancy; 89 risk of miscarriage was similar for women treated with chloroquine, quinine, or artesunate 90 Series non-artemisinin antimalarial drugs. The analysis also showed that the risk of stillbirth was lower in women who were treated with ACT than in those treated with quinine, possibly reflecting a higher efficacy of artemisinin treatment. 102 Another systematic review showed that, in the second and third trimester, artemether-lumefantrine was not associated with increased adverse pregnancy outcomes as compared with quinine or sulfadoxinepyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine. 73 Between 1948 and 1990, six studies reported amodiaquine use in pregnancy; only one study had adverse events, but information on these events was scarce. 103 A subsequent study showed that amodiaquine, given alone or in combination with sulfadoxinepyrimethamine during the second or third trimester, was not associated with liver toxicity or bone marrow depression. 104 In Ghana, pregnant women treated with amodiaquine alone or in combination with sulfadoxinepyrimethamine had an increased frequency of mild adverse events compared with those treated with sulfadoxine-pyrimethamine alone; there was no difference in miscarriages, stillbirths, neonatal jaundice, and neonatal deaths between the groups. 105 At standard doses, amodiaquine does not cause developmental malfor mations of the embryo or fetus and the adverse events seen during pregnancy are no more common than those associated with P falciparum malaria in pregnancy. 106 Since this study 106 was published, a smaller study reported that amodiaquine is safe and reasonably well tolerated. 55 Amodiaquine-artesunate was not associated with adverse birth outcomes in a 2009 study in Tanzania. 74 Similarly, the proportion of women who reported adverse events during the 7 days after treatment did not differ significantly between treatment groups (IPTp with sulfadoxine-pyrimethamine, and treatment with sulfadoxine-pyrimethamine or amodiaquineartesunate) with the exception of general weakness, which was slightly more common in women treated with amodiaquine-artesunate. 75 Dihydroartemisinin-piperaquine was well tolerated and had an acceptable safety profile in one arm of a trial in which more than 800 African pregnant women were treated in the second and third trimester. 28 These results are similar to those from other smaller studies done in Asia 50,76 and Africa. 57, 58 Although dihydroartemisininpiperaquine can cause prolongation of the QT interval, 79 no clinically significant prolongation of the QT interval was seen on 42 pregnant women receiving dihydroartemisinin-piperaquine. 77, 78 Initial concerns regarding the association between mefloquine and stillbirth came from a retrospective analysis in Thailand. 107 This finding was not supported by earlier studies that evaluated mefloquine for treatment of malaria in pregnancy, nor by later studies on mefloquineartesunate. [108] [109] [110] The prevalence of birth defects and fetal loss were similar to background rates in 2506 pregnant women exposed to mefloquine. 83 In 850 African women in the second and third trimester of pregnancy who had P falciparum malaria, mefloquine-artesunate was less well tolerated than was artemether-lumefantrine and dihydroartemisinin-piperaquine, and drug-related adverse events were more common with mefloquineartesunate than with artemether-lumefantrine or dihydroartemisinin-piperaquine; pregnancy outcomes were similar to other antimalarial treatments. 28 When mefloquine alone was used as IPTp, incidence of spontaneous abortions, stillbirths, and congenital anomalies did not differ significantly from incidence in the sulfadoxine-pyrimethamine groups, although adverse events were more common. 84 Adverse events were common, but mostly minor, in a study of pregnant Beninese women; 61 (65%) of 94 HIV-positive women and 300 (78%) of 385 HIV-negative women to whom two doses of mefloquine was given as IPTp had adverse events. Notably, mefloquine tolerability was better in HIV-positive women, a finding that might be explained by these women being more familiar with adverse events and thus less prone to report them. 111, 112 In two studies 113, 114 for prevention of malaria in HIV-positive and HIV-negative women in Africa, mefloquine was less well tolerated than was sulfadoxine-pyrimethamine. In the study of HIV-positive women, 113 the viral load and frequency of mother to child transmission of HIV was higher in the mefloquine group, but this result needs to be confirmed.
Sulfadoxine-pyrimethamine has been used extensively in pregnancy for treatment and IPTp, but formal safety studies are scarce. 36 Pyrimethamine causes dose-dependent embryotoxicity in rats, but not at humanequivalent doses. 87 In a case-control study, mothers whose babies had cleft palate had a higher exposure to sulfonamides than did controls. 87 Nevertheless, although use of folate antagonists in the first trimester is associated with neural tube defects, large case-control studies have shown that sulfadoxine-pyrimethamine given as IPTp does not increase the risk of teratogenesis. 85 In Malawi 80 and Sudan, 81 sulfadoxine-pyrimethamine plus artesunate given to pregnant women with P falciparum malaria was safe and well tolerated, although the sample size in both countries was small. Similarly, in The Gambia, exposure to sulfadoxine-pyrimethamine and a single dose of artesunate in pregnant women during a mass drug administration programme did not have any teratogenic, or any other harmful, effects. 82 Sulfadoxinepyrimethamine should not be given concurrently with co-trimoxazole because of their redundant mechanisms of action and synergistic worsening of adverse drug reactions. 86 No clinical association between sulfadoxinepyrimethamine and kernicterus has been reported. 85 
Quinine
The use of quinine in pregnancy is generally thought to be safe, and it is not associated with poor birth outcomes. 36 www.thelancet.com/infection Vol 18 April 2018 e141 Series Quinine causes prolongation of the QT interval, but no significant cardiotoxicity has been seen in large prospective studies. 88 Furthermore, quinine can sometimes cause hypoglycaemia, particularly in the second and third trimester, even in uncomplicated malaria. 5 In Uganda, the percentage of patients treated for uncomplicated malaria during pregnancy with at least one adverse event (most commonly tinnitus) was significantly higher in the quinine than it was in the artemether-lumefantrine arm. 25 
Chloroquine
Chloroquine has been described as safe throughout pregnancy. 89 Although chloroquine causes prolongation of the QT interval, no significant cardiotoxicity was reported in large prospective studies. 88 A study in Thailand showed that the risk of miscarriage was similar among women treated with chloroquine, quinine, or artesunate. 90
Access to treatment
Despite wide-scale adoption of the 2006 WHO recommendations 115 to use ACTs to treat uncomplicated malaria in the second and third trimester of pregnancy, access to parasitological diagnosis or appropriate antimalarial treatment remains low in many countries and regions. In a systematic review of women's access and provider practices, case management practices among health-care providers in the public, private, and retail sectors were generally poor. 116 Reliance on clinical diagnosis and poor adherence to treatment policy was consistently reported across different settings. 116 Adherence to treatment policy in the first trimester of pregnancy was significantly lower (28%) than in other trimesters (72%). 116 ACTs, which are currently contraindicated in the first trimester, 22, 115 were commonly prescribed either with quinine (recommended policy) [116] [117] [118] [119] or as monotherapy. 120 In western Kenya, correct prescription was seen in only five (24%) of 21 women in the first trimester who exited health facilities and in none of the 37 simulated clients attending drug outlets. In the second or third trimester, 48 (65%) of 74 pregnant women leaving health facilities and 15 (40%) of 38 women who visited drug outlets (simulated) had a correct prescription. Notably, 18 (49%) of 37 women in the first trimester who went to drug outlets were prescribed artemether-lumefantrine. 118 Drugs no longer recommended for treatment of P falciparum malaria in Africa were widely prescribed for women in all trimesters, including sulfadoxine-pyrimethamine (which is restricted for use as IPTp or prevention only) in Nigeria 117, [119] [120] [121] and Kenya, 118 and chloroquine in Nigeria. 117, 119, 121 Use of artemether and artesunate monotherapies were widely reported in Nigeria 117, [119] [120] [121] and in Uganda. 122 Correct treatment practices among health providers were associated with knowledge, 121, 122 training, 116, 118 availability of guidelines, 122 and facility type (public vs private, or drug shops). 116, 118 Prescribing practices were affected by concerns over side-effects, safety, availability, patient preference, and cost. 116 This research highlights the need for countries to provide quality training, guidelines, and job aids to all health professionals and other providers, particularly drug shops in the community, and to ensure both diagnostic tools and recommended treatments are available at all levels of the health system. Evidence for quality improvement initiatives that target public and private providers are also needed, alongside legislation to regulate which antimalarial drugs are licensed for sale.
Although pregnant women often report bouts of malaria, anthropological research has highlighted that their understanding of malaria symptoms overlap only partly with biomedical definitions and women can find it difficult to distinguish suspected malaria from pregnancyrelated symptoms. [123] [124] [125] [126] Such confusion contributed to delays in women seeking treatment in Mali and Kenya. 127 Women's choice of health-care provider was influenced by severity and duration of malaria episode, 123, 128 knowledge and perceptions of drug safety, drug availability, and cost and perceptions of health-care services, 116, 127 with the use of non-biomedical remedieshomemade or from a local healer-reported in Mali, 127 Nigeria, 129 South Sudan, 128 India, 130 and Papua New Guinea. 131 Social relationships influenced treatment seeking behaviour and some women, particularly younger women, sought advice or assistance from relatives. 123, 126 The existence of self-treatment, which is typically prompted by high costs of drugs or diagnostic tests, irregular drug supplies at health facilities, or previous poor quality care, or a combination, highlights the need for clear advice on antimalarial drugs and doses that are safe during pregnancy to be made widely available. 123
Conclusions and future directions
Over the past 10 years, the Malaria in Pregnancy Consortium and other research groups have carried out extensive research to improve the control of malaria in pregnancy, focusing on priorities outlined previously. 132 Evidence on the treatment of malaria during pregnancy has increased substantially. Malaria in pregnancy can be diagnosed by HRP2-based RDTs; available ACTs can be used for the treatment of malaria during the second and third trimester of pregnancy; and WHO might revise the guidelines on the use of artemisinins in the first trimester of pregnancy. This evidence needs to be translated into policy. However, poor quality delivery of health services across public, private, and retail sectors in most endemic regions shows that there is a pressing need for research to identify interventions for quality improvement that target users and providers. The priorities for policy implementation include health provider training on national policy guidelines for diagnosis and treatment of malaria in pregnancy. Additional research priorities are outlined in the panel. The continued use of monotherapies in pregnancy, and general use, requires Series national legislation to prohibit their availability and use. Pregnant women need access to information about which antimalarial drugs are safe.
Additionally, there is a need to establish efficient systems for pharmacovigilance that identify and report possible drug-related safety signals. Such surveillance is particularly difficult in low-income countries because of specific challenges, such as geographical remoteness of many health facilities, poor telecommunication systems, and inadequate education of health pro fessionals and patients. 36, 133 The safety of medications during pregnancy could be monitored by different prospective designs, including pregnancy registers, but these require substantial resources that are not readily available in most countries where malaria is endemic. Probabilistic record linkage to assess the risk of major congenital malformations and stillbirth is one possible approach, but medical registers would need to be well maintained. 134 To adequately address these programmatic challenges, improved dialogue and collaboration will be needed between researchers, policy makers, and funders.
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Search strategy and selection criteria
We searched PubMed for articles published between Jan 1, 2000, and June 31, 2017 using the terms "pregnan*" AND "malaria". We added additional terms when searching for literature on each specific topic. For diagnosis, we added "diagnostic tests". For treatment efficacy, we added "treatment*" AND "efficacy". For pharmacokinetics, we added "pharmacokinetic*". For safety, we added "safety". For access to treatment, we searched Web of Knowledge, OvidSP, and the Malaria in Pregnancy library for articles published since the most recent review on this topic (Hill and colleagues, 2014) using search terms "pregnan* AND "malaria" AND "treat*" OR "treatment seeking" OR "health seeking" OR "care seeking" OR "provider*" OR "ANC" OR "antenatal" OR "health provider" OR "health-work*" OR "health servic*" OR "drug shop" OR "community health worker" OR "CHW" OR "chemical-seller" OR "ADDO" OR "community drug dispens*" OR "formal" OR "informal" OR "case management" OR "control" OR "management" OR "diagno*" OR "prescrib*" OR "treat*" OR "practice*" OR "chloroquine" OR "CQ" OR "quinine" OR "ACT" OR "artemisinin-based combination therapy" OR "safe*" OR "refer*", AND "utilisation" OR "utilization" OR "coverage" OR "barrier*" OR "attendance" OR "compliance" OR "adherence" OR "attitude*" OR "knowledge" OR "practic*" OR "belie*" OR "perception*" OR "delivery" OR "delivery effectiv*" OR "determinant*" OR "distribut*" OR "evaluat*" OR "delivery system*" OR "predictor" OR "DOT*" OR "directly observed" OR "uptake" OR "behaviour*" OR "behavior*" OR "perception*" OR "accept*" OR "acceptance" OR "availability" OR "awareness" OR "recog*" OR "social" OR "cultur*" OR "socio-cultural" OR "societal". There were no language restrictions. 
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